Similar articles

• [Current treatment of hepatitis B].

  Suárez García E, Romero Gómez M, Grande Santamaría L. Suárez García E, et al. Gastroenterol Hepatol. 2001 Feb;24 Suppl 1:35-50. Gastroenterol Hepatol. 2001. PMID: 11279893 Spanish. No abstract available.
• Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.

  Hultgren C, Weiland O, Milich DR, Sällberg M. Hultgren C, et al. Clin Infect Dis. 1999 Dec;29(6):1575-7. doi: 10.1086/313518. Clin Infect Dis. 1999. PMID: 10585820 No abstract available.
• Hepatitis B virus infection--natural history and clinical consequences.

  Ganem D, Prince AM. Ganem D, et al. N Engl J Med. 2004 Mar 11;350(11):1118-29. doi: 10.1056/NEJMra031087. N Engl J Med. 2004. PMID: 15014185 Review. No abstract available.
• Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.

  Lai CL, Yuen MF, Hui CK, Garrido-Lestache S, Cheng CT, Lai YP. Lai CL, et al. J Med Virol. 2002 Jul;67(3):334-8. doi: 10.1002/jmv.10075. J Med Virol. 2002. PMID: 12116023 Clinical Trial.
• [Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].

  Ishikawa T, Kakumu S. Ishikawa T, et al. Nihon Rinsho. 2004 Aug;62 Suppl 8:331-5. Nihon Rinsho. 2004. PMID: 15453340 Review. Japanese. No abstract available.